Ipca Laboratories Ltd Stock Price Today (NSE: IPCALAB)
Fundamental Score
Ipca Laboratories Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Ipca Laboratories Ltd share price today is ₹1453.80, up +0.00% on NSE/BSE as of 20 February 2026. Ipca Laboratories Ltd (IPCALAB) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹36.04K (Cr). The 52-week high for IPCALAB share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 36.41x, IPCALAB is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 12.75% and a debt-to-equity ratio of 0.17.
Ipca Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Ipca Laboratories Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Ipca Laboratories Share Price Analysis: A Strategic Growth Perspective
The pharmaceutical sector faces a compelling challenge: balancing innovation with affordability, especially as generics become increasingly crucial for global healthcare access. This analysis examines the factors influencing the Ipca Laboratories share price, currently trading at ₹1416.70, from a growth strategist's perspective. We'll delve into its valuation, profitability, and competitive positioning within the Indian pharmaceutical landscape. The company's current PE ratio of 36.41 suggests investor expectations of future earnings growth.
A crucial metric for assessing Ipca's long-term sustainability is its Return on Capital Employed (ROCE) of 14.72%. This indicates the efficiency with which the company is using its capital to generate profits. A higher ROCE generally implies a stronger competitive advantage, or "moat," as it suggests the company can generate superior returns compared to its peers. However, the true strength of this moat needs to be assessed in the context of industry averages and the sustainability of these returns over time. A high ROCE that is easily replicable by competitors offers a weaker competitive advantage.
When evaluating Ipca, it's important to consider its peer group, including companies like
Mankind Pharma Ltd. While a complete assessment would require deeper investigation, anecdotal evidence suggests varying levels of management quality across these firms. A comparative analysis of leadership's strategic vision, capital allocation decisions, and operational efficiency is critical for understanding long-term growth prospects. Specifically, it is worth observing how Mankind Pharma Ltd approaches diversification and pricing strategies, and comparing this with Ipca's approach.Ultimately, a comprehensive understanding of the drivers impacting the Ipca Laboratories share price requires a deeper dive into its financial statements, growth pipeline, and competitive landscape. This analysis forms part of a wider 80-parameter fundamental audit, verified by Sweta Mishra, designed to uncover potential risks and opportunities for strategic growth. The purpose of this analysis is informational and observational, and should not be construed as a recommendation to buy or sell Ipca Laboratories shares.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Ipca Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of IPCALAB across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Operating Margins (20.22%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (41.49%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Consistent Growth Track Record (14.01% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Conservative Debt Levels (D/E: 0.17)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (20.38x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹2552.40 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Strong Institutional Confidence (FII+DII: 46.87%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
0 factors identified
No significant concerns identified in current analysis.
Ipca Laboratories Ltd Financial Statements
Comprehensive financial data for Ipca Laboratories Ltd including income statement, balance sheet and cash flow
About IPCALAB (Ipca Laboratories Ltd)
Ipca Laboratories Ltd (IPCALAB) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹36.04K (Cr). Ipca Laboratories Ltd has delivered a Return on Equity (ROE) of 12.75% and a ROCE of 14.72%. The debt-to-equity ratio stands at 0.17, reflecting the company's capital structure. Investors tracking IPCALAB share price can monitor key metrics including P/E ratio, promoter holding of 44.72%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
IPCALAB Share Price: Frequently Asked Questions
What is the current share price of Ipca Laboratories Ltd (IPCALAB)?
As of 20 Feb 2026, 05:03 am IST, Ipca Laboratories Ltd share price is ₹1453.80. The IPCALAB stock has a market capitalisation of ₹36.04K (Cr) on NSE/BSE.
Is IPCALAB share price Overvalued or Undervalued?
IPCALAB share price is currently trading at a P/E ratio of 36.41x, compared to the industry average of 31.77x. Based on this relative valuation, the Ipca Laboratories Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of IPCALAB share price?
The 52-week high of IPCALAB share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Ipca Laboratories Ltd share price?
Key factors influencing IPCALAB share price include quarterly earnings growth (Sales Growth: 8.56%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Ipca Laboratories Ltd a good stock for long-term investment?
Ipca Laboratories Ltd shows a 5-year Profit Growth of 7.24% and an ROE of 12.75%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.17 before investing in IPCALAB shares.
How does Ipca Laboratories Ltd compare with its industry peers?
Ipca Laboratories Ltd competes with major peers in the Pharmaceuticals. Investors should compare IPCALAB share price P/E of 36.41x and ROE of 12.75% against the industry averages to determine competitive standing.
What is the P/E ratio of IPCALAB and what does it mean?
IPCALAB share price has a P/E ratio of 36.41x compared to the industry average of 31.77x. Investors pay ₹36 for every ₹1 of annual earnings.
How is IPCALAB performing according to Bull Run's analysis?
IPCALAB has a Bull Run fundamental score of 56.6/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does IPCALAB belong to?
IPCALAB operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Ipca Laboratories Ltd share price.
What is Return on Equity (ROE) and why is it important for IPCALAB?
IPCALAB has an ROE of 12.75%, which shows decent profitability but room for improvement. ROE measures how efficiently Ipca Laboratories Ltd generates profits from shareholders capital.
How is IPCALAB debt-to-equity ratio and what does it indicate?
IPCALAB has a debt-to-equity ratio of 0.17, which indicates conservative financing with low financial risk.
What is IPCALAB dividend yield and is it a good dividend stock?
IPCALAB offers a dividend yield of 0.28%, meaning you receive ₹0.28 annual dividend for every ₹100 invested in Ipca Laboratories Ltd shares.
How has IPCALAB share price grown over the past 5 years?
IPCALAB has achieved 5-year growth rates of: Sales Growth 14.01%, Profit Growth 7.24%, and EPS Growth 7.16%.
What is the promoter holding in IPCALAB and why does it matter?
Promoters hold 44.72% of IPCALAB shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Ipca Laboratories Ltd.
What is IPCALAB market capitalisation category?
IPCALAB has a market capitalisation of ₹36040 crores, placing it in the Large-cap category.
How volatile is IPCALAB stock?
IPCALAB has a beta of N/A. A beta > 1 suggests the Ipca Laboratories Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is IPCALAB operating profit margin trend?
IPCALAB has a 5-year average Operating Profit Margin (OPM) of 20.22%, indicating the company's operational efficiency.
How is IPCALAB quarterly performance?
Recent quarterly performance shows Ipca Laboratories Ltd YoY Sales Growth of 8.56% and YoY Profit Growth of 41.49%.
What is the institutional holding pattern in IPCALAB?
IPCALAB has FII holding of 10.42% and DII holding of 36.45%. Significant institutional holding often suggests professional confidence in the Ipca Laboratories Ltd stock.